Home > Treatment Options > Tumor Suppressors > Clinical Trials >

Aspirin

Last Updated: 02/16/18

Status: Pre-Clinical Trial


Chemical Structure, Aspirin
Administered By: Pill - Oral
Tumor Target: Vestibular Schwannoma
NF2 Trials NCT0307999
"Aspirin in Patients With Vestibular Schwannoma"
  • Recruitment Status: Not yet recruiting
  • First Posted: March 15, 2017
  • Last Update Posted: November 17, 2017
Formula C9H8O4

The over-the-counter medication (OTC) aspirin, includes both blood thinners and nonsteroidal anti-inflammatory agents which has been found beneficial to Vestibular Schwannoma (VS) tumor control in mouse trials. Common side effects for the use of aspirin of tinnitus, nausea/vomiting, dizziness, hearing loss, and kidney failure are also common effects of VS tumor growth, specifically from vestibular nerve and cochlear nerve damage, as well as brain tumor-induced migraines.

Aspirin use for Vestibular Schwannoma (VS) may be a good option for individuals who have NF2 but have not developed any nerve damage from existing VS yet and are looking to delay issue development before it occurs. Options this simple are the reason for confirmed proof of NF2 diagnosis if another family has NF2, or if other symptoms of NF2 are present.

While aspirin is an over the counter medication, discuss considering it as something to take with your doctor if considering it.

* Many prescriptions and supplements are known to have negative interactions with aspirin.

Side Effects

  • thin blood
  • easy bruising/bleeding
  • gastrointestinal bleeding
  • difficulty hearing
  • tinnitus (ringing in the ears)
  • kidney problems (watch for change in urine color or amount of urine)
  • persistent or severe nausea/vomiting
  • unexplained tiredness
  • dizziness
  • yellowing eyes/skin

Sources

  1. "Aspirin." WebMd. (Date Reviewed: 2018)
    Source: https://www.webmd.com/drugs/2/drug-1082-3/aspirin-oral/aspirin-oral/details
  2. Van Gompel, Jamie J., et al. "Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Emerging Therapies for the Treatment of Patients With Vestibular Schwannomas." Neurosurgery (2018).
    Source: https://academic.oup.com/neurosurgery/article/82/2/E52/4764051 | DOI: 10.1093/neuros/nyx516
  3. Van, JJ Gompel, et al. "Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Emerging Therapies for the Treatment of Patients With Vestibular Schwannomas." Neurosurgery (2017).
    Source: http://europepmc.org/abstract/med/29309638 | DOI: 10.1093/neuros/nyx516
  4. Kandathil, Cherian K., et al. "Aspirin intake correlates with halted growth of sporadic vestibular schwannoma in vivo." Otology & Neurotology 35.2 (2014): 353-357.
    Source: https://journals.lww.com/otology-neurotology/Abstract/2014/02000/Aspirin_Intake_Correlates_With_Halted_Growth_of.25.aspx | DOI: 10.1097/MAO.0000000000000189
  5. Vijayan, M. "Structure and interactions of aspirin-like drugs." Proceedings of the Indian Academy of Sciences-Chemical Sciences. Vol. 92. No. 4-5. Springer India, (1983). Source: https://link.springer.com/article/10.1007/BF02839150 | DOI: 10.1007/BF02839150